all report title image

Erectile Dysfunction Treatment Market Analysis & Forecast: 2026-2033

Erectile Dysfunction Treatment Market, By Drugs (Sildenafil (Viagra), Vardenafil (Levitra Staxyn), Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), Others), By Route of Administration (Oral drugs, Injections, Topical application), By Distribution Channel (Hospital Pharmacies, Retail  Pharmacies, Online  Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : 28 Apr, 2026
  • Code : CMI200
  • Page number :180
  • Formats :
      Excel and PDF :
  • Industry : Pharmaceutical
  • Historical Range : 2020 - 2024
  • Forecast Period : 2026-2033

Erectile Dysfunction Treatment Market is estimated to be valued at USD 5.67 Bn in 2026 and is expected to reach USD 9.59 Bn in 2033, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2026 to 2033.

Analysts’ Views on the Global Erectile Dysfunction Treatment Market:

The global erectile dysfunction treatment market has been steadily growing due to factors such as an aging population, changing lifestyle patterns, increased awareness, and reduced stigma associated with seeking treatment for Erectile Dysfunction (ED). Research and development in the field of ED treatment have led to the exploration of new therapies. Some of these include stem cell therapy and gene therapy.

Figure 1. Global Erectile Dysfunction Treatment Market Share (%), By Product Type, 2026

ERECTILE DYSFUNCTION TREATMENT MARKET

To learn more about this report, Download Free Sample

Global Erectile Dysfunction Treatment Market - Drivers

  • Increasing prevalence of erectile dysfunction: The increasing incidence of erectile dysfunction is expected to propel the growth of the global erectile dysfunction treatment market over the forecast period. For instance, according to an article published by Jobson Medical Information LLC which delivers comprehensive medical information and communications to the healthcare community,  in June 2022, annual erectile dysfunction incidence rate increased with each decade of age and was 12.4 cases per 1,000 man-years (96% CI 9.0 to 16.9), 29.8 (24.0 to 37.0) and 46.4 (36.9 to 58.4) for men 40 to 49, 50 to 59 and 60 to 69 years old, respectively.
  • Increasing product launches for the treatment of erectile dysfunction by market players: Increasing product launches for the treatment of erectile dysfunction by market players which are expected to drive the global erectile dysfunction treatment market growth over the forecast period. For instance, in August 2023, Mangoceuticals, Inc., a company focused on developing, marketing, and selling, a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated Erectile Dysfunction (ED) drug branded “Mango,” announced the official commercial launch of its second Mango ED product, which leverages the company’s existing custom compound alongside Sildenafil, the active ingredient found in Viagra.

Figure 2. Global Erectile Dysfunction Treatment Market Share (%), By Region, 2026

ERECTILE DYSFUNCTION TREATMENT MARKET

To learn more about this report, Download Free Sample

Global Erectile Dysfunction Treatment Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global erectile dysfunction treatment market over the forecast period. North America is estimated to hold 33.9% of the market share in 2026 owing to key players operating in the market focusing on product launches. For instance, in June 2026, Futura Medical, a research and development pharmaceutical company, had developed Eroxon, a topical gel for erectile dysfunction, which has been authorized for over-the-counter marketing in the U.S.

Erectile Dysfunction Treatment Market  Report Coverage

Report Coverage Details
Base Year: 2025 Market Size in 2026: USD 5.67 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 7.8% 2033 Value Projection: USD 9.59 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drugs: Sildenafil (Viagra), Vardenafil (Levitra Staxyn), Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), Others 
  • By Route of Administration: Oral drugs, Injections, Topical application 
  • By Distribution Channel: Hospital Pharmacies, Retail  Pharmacies, Online  Pharmacies 
Companies covered:

Mangoceuticals, Inc, Futura Medical,  CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific, Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust  Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC

Growth Drivers:
  • Increasing prevalence of erectile dysfunction
  • Increasing product launches for the treatment of erectile dysfunction by market players
Restraints & Challenges:
  • Ban on erectile dysfunction drugs

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Global Erectile Dysfunction Treatment Market Segmentation:

The global erectile dysfunction treatment market report is segmented into by drugs, by route of administration, by distribution channel, and by region.

  • By Drugs, the market is segmented into Sildenafil (Viagra), Vardenafil (Levitra Staxyn) , Tadalafil (Cialis), Avanafil (Stendra), Udenafil (Zydena), and others. Out of which, the Sildenafil (Viagra) segment is expected to hold a dominant position in the global erectile dysfunction treatment market during the forecast period, and this is attributed to key players operating in the market focusing on inorganic strategies to offer Sildenafil (Viagra).
  • By Route of Administration, the market is segmented into oral drugs, injection, and topical application. Out of which, oral drugs is expected to dominate the market over the forecast period, and this is attributed to the adoption of oral drugs as it can be self-administered and economical which drives the growth of the segment .
  • By Distribution Channel, the market is segmented into hospital pharmacies, offline pharmacies, and online pharmacies. Out of which, retail pharmacies is expected to dominate the market over the forecast period, and this is attributed to their easy access to medicine and availability of generic ED drugs through retail pharmacies.

Among all the segmentation, the product type segment is expected to dominate the market over the forecast period, and this is attributed to increasing inorganic and organic growth strategies by market players for the treatment of erectile dysfunction.

Global Erectile Dysfunction Treatment Market - Cross Sectional Analysis:

The key players focusing on organic growth strategies, such as product approvals for erectile dysfunction, is also expected to drive the market growth of in the North America region over the forecast period. For instance, in March 2022, Lupin Limited (Lupin) India based multinational pharmaceutical company, announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic equivalent of Revatio for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC, a global pharmaceutical company. Sildenafil is used to treat impotence or erectile dysfunction-ED

Global Erectile Dysfunction Treatment Market: Key Developments

In January 2020, Greenstone, is part of the Upjohn business and a wholly owned subsidiary of Pfizer Inc., and Roman, an innovative digital healthcare clinic for men, announced a supply agreement to offer Roman members access to the only U.S. FDA-approved authorized generic version of Viagra (sildenafil citrate).

In December 2020, Glenmark Pharmaceuticals Ltd. an India-based multinational pharmaceutical company, received final approval from the U.S. Food and Drug Administration (FDA) for Tadalafil tablets USP in the strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil tablets are used to treat erectile dysfunction by increasing blood flow to the penis during sexual stimulation.

Global Erectile Dysfunction Treatment Market: Key Trends

  • Increasing awareness for erectile dysfunction treatment : Introduction of erectile dysfunction treatment with advanced technology in the market is expected to drive the growth of the global erectile dysfunction treatment market over the forecast period. For instance, in August 2021, Pfizer Upjohn, a division of Pfizer, a the biopharmaceutical company, launched a campaign, #KeepItReal, to help make conversations about Erectile Dysfunction (ED) less of a taboo for couples, enabling them to discuss their problems and find a suitable solution. The campaign is conceptualized by Edelman India, is a global communications firm that partners with businesses and organizations to evolve, promote, and protect their brands and reputations.

Global Erectile Dysfunction Treatment Market: Restraint

  • Ban on erectile dysfunction drugs: Ban on erectile dysfunction drugs is expected to hinder the market growth over the forecast period. For instance, in August 2022, Indiana Representative proposed an amendment to Indiana's abortion law to outlaw the sale, prescription, or distribution of erectile dysfunction drugs and other male sexual incompetence drugs.Market players should collaborate closely with regulatory agencies to understand the specific reasons for the ban and work on addressing those concerns. Present clear evidence of the drug's benefits and the steps taken to mitigate any potential risks.

Global Erectile Dysfunction Treatment Market - Key Players

The major players operating in the global erectile dysfunction treatment market include Mangoceuticals, Inc, Futura Medical,  CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific , Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust  Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLC.

Sources

Primary Research Interviews

  • Urologists and sexual medicine specialists prescribing PDE5 inhibitors and second-line therapies
  • Pharmaceutical manufacturers of sildenafil, tadalafil, vardenafil, avanafil and intracavernosal/intraurethral therapies (e.g., Pfizer, Eli Lilly, Bayer, Metuchen Pharmaceuticals)
  • Generic drug manufacturers and API suppliers for ED therapeutics
  • Telehealth men's health platform operators (e.g., Hims, Ro) and their medical directors
  • Retail and online pharmacy procurement heads for ED medications
  • Payers and PBMs managing ED drug formulary coverage

Databases

  • U.S. FDA Orange Book and Drugs@FDA databases
  • European Medicines Agency (EMA) public assessment reports
  • Centers for Medicare & Medicaid Services (CMS) drug pricing and utilization data
  • National Institutes of Health (NIH) / NIDDK men's health statistics
  • WHO Essential Medicines and Health Products Information Portal
  • OECD Health Statistics – pharmaceutical consumption

Magazines

  • Urology Times
  • Renal & Urology News
  • Pharmaceutical Executive
  • Pharmacy Times
  • Scrip / Pink Sheet (Informa Pharma Intelligence)

Journals

  • The Journal of Sexual Medicine (ISSM)
  • The Journal of Urology (AUA)
  • European Urology (EAU)
  • International Journal of Impotence Research (Nature)
  • Sexual Medicine Reviews
  • Andrology (Wiley)

Newspapers

  • Reuters Health & Pharma
  • Financial Times – Pharmaceuticals coverage
  • The Wall Street Journal – Health section

Associations

  • American Urological Association (AUA)
  • European Association of Urology (EAU)
  • International Society for Sexual Medicine (ISSM)
  • Sexual Medicine Society of North America (SMSNA)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Generic Pharmaceutical Association / AAM (Association for Accessible Medicines)

Public Domain Sources

  • U.S. Food and Drug Administration (FDA) – Center for Drug Evaluation and Research (CDER)
  • European Medicines Agency (EMA)
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • ClinicalTrials.gov
  • ResearchGate publications on erectile dysfunction pharmacotherapy

Proprietary Elements

  • CMI Data Analytics Tool
  • CMI Proprietary Repository of Men's Health Pharmaceuticals Intelligence (Last 10 Years)

*Definition: Erectile Dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as men get older. But it's not a natural part of aging.

Share

Share

About Author

Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.

Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The Erectile Dysfunction Treatment Market is estimated to be valued at USD 5.67 Bn in 2026, and is expected to reach USD 9.59 Bn by 2033.

The CAGR of the Erectile Dysfunction Treatment Market is projected to be 7.8% from 2026 to 2033.

Increasing prevalence of erectile dysfunction and increasing product launches for the treatment of erectile dysfunction by market players is expected to drive the market growth.

Ban on erectile dysfunction drug is the leading product type segment in the market.

Ildenafil (Viagra) is expected to hinder the market growth over the forecast period.

The major players operating in the market are Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific , Cipla Ltd, Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust  Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic LLLC.
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2026 Coherent Market Insights Pvt Ltd. All Rights Reserved.